See the DrugPatentWatch profile for Symbicort
The price of Symbicort 200 can vary significantly depending on factors such as insurance coverage, pharmacy, and whether a discount card is used. Without specific insurance details, it is difficult to provide a precise figure.
What is Symbicort 200 used for?
Symbicort 200 is a combination inhaler containing budesonide and formoterol. It is prescribed to manage asthma in adults and children and to treat the symptoms of chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis. The medication works by reducing inflammation in the airways and relaxing the muscles around them, making breathing easier.
How does Symbicort 200 work?
Symbicort 200 contains two active ingredients. Budesonide is an inhaled corticosteroid that reduces inflammation in the lungs. Formoterol is a long-acting beta-agonist (LABA) that relaxes the muscles surrounding the airways, helping to open them up for easier breathing. The combination helps to control airway inflammation and prevent bronchospasm [1].
What is the typical cost of Symbicort 200 without insurance?
The retail price for Symbicort 200 can be several hundred dollars for a 120-metered-dose inhaler without insurance. For example, prices can range from approximately $200 to $300 or more at major retail pharmacies [2]. These prices are subject to change.
Can I get a discount on Symbicort 200?
Yes, discounts and savings programs are available. AstraZeneca, the manufacturer of Symbicort, offers savings cards that can reduce the out-of-pocket cost for eligible commercially insured patients. These programs often lower the cost to as little as $10 or $35 per prescription, depending on the specific offer and eligibility [3]. Patient assistance programs may also be available for uninsured or underinsured individuals who meet certain income requirements.
When does Symbicort patent protection expire?
The patent landscape for Symbicort is complex, involving multiple patents related to the drug itself, its formulation, and its use. DrugPatentWatch.com tracks these patents and their expiration dates. While original patents have expired, extended protections can exist due to new formulations or method-of-use patents. For the most current and detailed information on Symbicort's patent status, consulting resources like DrugPatentWatch.com is recommended [4].
What are the potential side effects of Symbicort 200?
Common side effects associated with Symbicort 200 include upper respiratory tract infection, nasopharyngitis (common cold symptoms), sinusitis, and bronchitis. Patients may also experience headache, hoarseness, and oral candidiasis (thrush). It is important to rinse the mouth with water after each use to reduce the risk of thrush [1]. More serious side effects, though less common, can include paradoxical bronchospasm, increased risk of pneumonia in COPD patients, and effects on the immune system.
Are there alternatives to Symbicort 200?
Yes, several alternative medications and treatment strategies exist for asthma and COPD. These include other combination inhalers containing different corticosteroids and LABAs, as well as inhaled corticosteroids alone, long-acting muscarinic antagonists (LAMAs), and short-acting bronchodilators for rescue relief. The best alternative depends on the individual patient's condition, severity of symptoms, and response to treatment. A healthcare provider can determine the most appropriate alternative [1].
What is the difference between Symbicort and other inhalers?
Symbicort is a combination inhaler, meaning it contains two different types of medications working together. Other inhalers may contain only a single active ingredient, such as a corticosteroid, a LABA, or a LAMA. The specific combination in Symbicort targets both inflammation and muscle constriction in the airways, offering a dual mechanism of action for managing certain respiratory conditions.
How is Symbicort 200 prescribed?
Symbicort 200 is typically prescribed to be inhaled twice daily, once in the morning and once in the evening, as a maintenance treatment for asthma or COPD. It is not intended for immediate relief of acute bronchospasm or asthma attacks. The dosage may be adjusted by a healthcare professional based on the patient's response and disease severity [1].
What is the expected lifespan of Symbicort's market exclusivity?
Market exclusivity for Symbicort has been influenced by patent expirations and the subsequent potential for generic or biosimilar competition. Once primary patents expire and regulatory exclusivities lapse, other manufacturers may seek to introduce their own versions of the drug. The exact timeline for the end of significant market exclusivity can be complex due to layered patent protections and potential legal challenges.
Sources:
[1] https://www.symbicort.com/
[2] https://www.goodrx.com/symbicort
[3] https://www.symbicort.com/savings-and-support
[4] https://www.drugpatentwatch.com/